Claims
- 1. A method of improving wound healing comprising the steps of:
a) administering a Smad3 inhibitor to a patient in need thereof; and b) measuring improvement of wound healing.
- 2. The method of claim 1, wherein said Smad3 inhibitor is a peptide.
- 3. The method of claim 1, wherein said Smad3 inhibitor is an antisense molecule.
- 4. The method of claim 1, wherein said Smad3 inhibitor is a ribozyme.
- 5. A method of improving wound healing comprising the steps of:
a) identifying a patient in need of improvement of wound healing; and b) administering a Smad3 inhibitor to said patient in need thereof.
- 6. The method of claim 5, wherein said Smad3 inhibitor is a peptide.
- 7. The method of claim 5, wherein said Smad3 inhibitor is an antisense molecule.
- 8. The method of claim 5, wherein said Smad3 inhibitor is a ribozyme.
- 9. A method of preventing fibrosis comprising the steps of:
a) administering a Smad3 inhibitor to a patient in need thereof; and b) measuring protection against fibrosis.
- 10. The method of claim 9, wherein said Smad3 inhibitor is a peptide.
- 11. The method of claim 9, wherein said Smad3 inhibitor is an antisense molecule.
- 12. The method of claim 9, wherein said Smad3 inhibitor is a ribozyme.
- 13. A method of preventing fibrosis comprising the steps of:
a) identifying a patient in need of protection against fibrosis; and b) administering a Smad3 inhibitor to said patient in need thereof.
- 14. The method of claim 13, wherein said Smad3 inhibitor is a peptide.
- 15. The method of claim 13, wherein said Smad3 inhibitor is an antisense molecule.
- 16. The method of claim 13, wherein said Smad3 inhibitor is a ribozyme.
- 17. A method of identifying a compound that can be used to improve wound healing comprising the steps of:
a) administering a test Smad3 inhibitor to a subject; and b) measuring the effect on wound healing, wherein a compound is selected as a candidate on the basis of improvement of wound healing.
- 18. The method of claim 17, wherein said Smad3 inhibitor is a peptide.
- 19. The method of claim 17, wherein said Smad3 inhibitor is an antisense molecule.
- 20. The method of claim 17, wherein said Smad3 inhibitor is a ribozyme.
- 21. A method of identifying a compound that can be used to protect against fibrosis comprising the steps of:
a) administering a test Smad3 inhibitor to a subject; and b) measuring the effect on fibrosis, wherein a compound is selected as a candidate on the basis of protection against fibrosis.
- 22. The method of claim 21, wherein said Smad3 inhibitor is a peptide.
- 23. The method of claim 21, wherein said Smad3 inhibitor is an antisense molecule.
- 24. The method of claim 21, wherein said Smad3 inhibitor is a ribozyme.
- 25. A method of making a pharmaceutical comprising the step of combining the compound identified by claim 17 with a pharmaceutical carrier.
- 26. A method of making a pharmaceutical comprising the step of combining the compound identified by claim 21 with a pharmaceutical carrier.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of international application number PCT/US00/13725, and claims the benefit of priority of international application number PCT/US00/13725 having international filing date of May 19, 2000, designating the United States of America and published in English, which is hereby expressly incorporated by reference in its entirety.
Continuations (1)
|
Number |
Date |
Country |
Parent |
PCT/US00/13725 |
May 2000 |
US |
Child |
10299886 |
Nov 2002 |
US |